Description
+ Include: 21 videos + 21 pdfs, size: 5.58 GB
+ Target Audience: hematologist, physicians, researchers, fellows, advanced practice providers, who provide care for patients undergoing HCT
+ Sample video: contact me for sample video
+ Information:
Friday, April 27, 2018, 7:00 AM – Saturday, April 28, 2018, 1:00 PM EST, Zuckerman Research Center 417 E 68th St, New York, NY
More than 10,000 hematopoietic cell transplantations (HCT) are performed annually in the United States as a potentially curative treatment for over 70 life-threatening illnesses including hematologic cancers, genetic disorders, and other diseases. Despite significant advances in supportive care and improvements in HCT outcomes, 1 in every 3 patients may succumb to HCT-related toxicities, half of which are not related to graft-versus-host disease (GVHD). Following the successful examples of the international symposia focusing on GVHD and relapse after HCT, we are convening the ‘1st International Symposium on Hematopoietic Cell Transplantation-Related Toxicities.’
This symposium will bring together experts and thought leaders from around the world in the fields of HCT and related medical subspecialties. Speakers will discuss mechanisms of toxicities and symptom burden after HCT in order to identify best practices to both prevent and treat HCT-related toxicities. Over the 2-day symposium, speakers and attendees will also convene in dedicated sessions that will facilitate collaborative efforts in planning future research aimed at mitigating serious toxicities, reducing symptom burden, and improving patients’ outcomes.
Target Audience
The target audience for this symposium includes physicians, researchers, fellows, advanced practice providers, nurses, and pharmacists who provide care for patients undergoing HCT.
- Discuss the causes and mechanisms of toxicities and symptom burden after HCT in order to identify best practices to prevent and treat them.
- Understand the role of vascular endothelial cell damage as a key driver of many toxicities after HCT.
+ Topics:
Cardiovascular Toxicities.mp4
Cardiovascular Toxicities.pdf
Combating Multidrug-resistant Bacterial Infections During Allogeneic-HCT.mp4
Combating Multidrug-resistant Bacterial Infections During Allogeneic-HCT.pdf
Endothelial Cell Damage as Common Pathway for Toxicity.mp4
Harnessing the Microbiome to Improve Transplant Outcomes.mp4
Harnessing the Microbiome to Improve Transplant Outcomes.pdf
HCT_Toxicities_2018Brochure.pdf
How to Utilize the CIBMTR and BMT CTN to Reduce Toxicities.mp4
How to Utilize the CIBMTR and BMT CTN to Reduce Toxicities.pdf
Idiopathic Pneumonia Syndrome.mp4
Idiopathic Pneumonia Syndrome.pdf
Immune Reconstitution.mp4
Immune Reconstitution.pdf
Introduction & Welcome.mp4
Introduction & Welcome.pdf
Long Term Survivorship Issues.mp4
Long Term Survivorship Issues.pdf
Mechanisms of Radiation Toxicity.mp4
Mechanisms of Radiation Toxicity.pdf
Mucosal Toxicities.mp4
Mucosal Toxicities.pdf
Neurologic Toxicities.mp4
Neurologic Toxicities.pdf
Novel Strategies to Reduce CMV Disease in Transplant Patients.mp4
Novel Strategies to Reduce CMV Disease in Transplant Patients.pdf
Pharmacokinetic Assays and Methodologies.mp4
Pharmacokinetic Assays and Methodologies.pdf
Pharmacokinetics of Alkylators.mp4
Pharmacokinetics of Alkylators.pdf
Pharmacology of High Dose Therapy.mp4
Pharmacology of High Dose Therapy.pdf
Proposed Biomarkers for Endothelial Cell Damage.mp4
Proposed Biomarkers for Endothelial Cell Damage.pdf
Pulmonary Toxicities.mp4
Pulmonary Toxicities.pdf
Renal Toxicities.mp4
Renal Toxicities.pdf
Sinusoidal Obstruction Syndrome.mp4
Sinusoidal Obstruction Syndrome.pdf
Thrombotic Microangiopathy.mp4
Thrombotic Microangiopathy.pdf
Reviews
There are no reviews yet.